Speakers

Prof  Georgina Long

Convenor Immuno-Oncology Forum

Biography

Professor Georgina Long is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney.

Professor Long leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. In recognition of her ground-breaking research, Professor Long has received a number of awards, including the prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016, and a number of recent CINSW Premier’s Awards for Outstanding Cancer Research: In 2014, she was awarded the Wildfire Award for the most highly-cited, original, peer-reviewed article published in 2011; and in 2013 she was named the Outstanding Cancer Research Fellow.

Professor Long is the author of over 135 peer-reviewed publications in clinical and translational research in melanoma since 2011, including the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 120 occasions. She is President-elect for the prestigious international Society for Melanoma Research (President from 2018), is Chair of the ASCO Scientific Committee for melanoma and skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

Dr Michael A. Postow

International Speaker

Biography

Michael Postow, MD, is a medical oncologist on faculty at Memorial Sloan Kettering Cancer Center.  He sees patients with advanced melanoma and conducts clinical trials of new immunotherapy approaches.  He was directly involved with the development of the combination of ipilimumab and nivolumab for patients with advanced melanoma and led the phase 2 trial which resulted in FDA approval of this combination.  His research describing the abscopal effect in a patient with melanoma has led to many ongoing clinical trials testing whether adding radiotherapy to immunotherapy improves outcomes and has been supported by several research grants from the American Society of Clinical Oncology.

He has published over 100 manuscripts on melanoma and immunotherapy and has first or senior author manuscripts in the New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology.  He enjoys traveling around the country and internationally to speak about topics related to immunotherapy research and treatment of advanced melanoma. In his spare time, he enjoys spending time with his wife and friends, playing guitar and piano, sailing, and skiing. 

Prof  Ben Solomon

Planning Committee – Immuno-Oncology Forum

Biography

Professor Ben Solomon is a medical oncologist in the Lung Service and the Head & Neck service. He is the Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division. He has an interest in translational lung cancer research and completed a PhD investigating the mechanisms by which EGFR inhibition enhance the effects of radiation, and subsequent postdoctoral studies at the University of Colorado investigating novel predictive markers for therapy with EGFR inhibitors.

A / Prof  Tom John

Planning Committee – Immuno-Oncology Forum

Biography

Associate Professor Thomas John is a medical oncologist specialising in Thoracic malignancies and genetics. He received his medical degree from Monash University and PhD from University of Melbourne in 2008. He underwent post-doctoral research using PDX models of NSCLC under the guidance of Prof Ming Tsao and Frances Shepherd in Toronto. He has received awards from the American Society of Clinical Oncology as well as the American Association for Cancer Research for his research into lung cancer and melanoma. He leads a laboratory group researching both lung cancer and mesothelioma with an interest in immunology, methylation and novel targets. He is funded by the National Health and Medical Research Council and the Cancer Council of Australia.

His research includes studying the immune microenvironment in lung cancer, mesothelioma and neuroendocrine tumours. In addition his laboratory group are investigating novel therapies and targets in mesothelioma. Currently his group are using mouse models to investigate new antibody drug conjugates and anti-apoptotic therapies in mesothelioma.

He has collaborations with other mesothelioma researchers across Australia, the Swiss Oncology group (SAKK), Prof Ming-Sound Tsao in Toronto, Canada and Prof Dean Fennel in the UK.

A /Prof   Sherene loi

Planning Committee – Immuno-Oncology Forum

Biography

Sherene Loi MD, PhD, is a medical oncologist specializing in the treatment of breast cancer. She also leads a lab that focuses on genomics and novel therapeutics in breast cancer, particularly understanding the genomic and immune interface in breast cancer patients. Her interest is also the development of novel therapeutics in the preclinical and clinical space. In preclinical models, A/Prof Loi and colleagues have shown that combination immunotherapy with anti-HER2 therapy is synergistic and effective and as a result, a phase II trial testing the efficacy of immunotherapy with trastuzumab is currently ongoing.

A/Prof Loi completed her medical oncology training in Melbourne, Australia. She worked in Brussels, Belgium at the Breast International Group clinical trials headquarters for nearly 8 years before returning to the Peter MacCallum Cancer Centre in Melbourne, Australia where her breast cancer practice and lab are located. She is also an active member of the Scientific Advisory Committee of the Australian and New Zealand Breast Cancer Trials Group (ANZBCTG) and co-chairs the Translational Working Group of the International Breast Cancer Study Group (IBCSG). She is the current holder of the Cancer Council Victoria John Colebatch Clinical Fellowship and a research fellow of the Breast Cancer Research Foundation (BCRF) based in New York, one of only two Australians to have been recognized for their research by this US-based organization. 

Dr  Alex Menzies

Planning Committee – Immuno-Oncology Forum

Biography

Dr Alex Menzies is a Medical Oncologist and Senior Research Fellow at Melanoma Institute Australia, Royal North Shore Hospital and The University of Sydney in Sydney, Australia. He completed specialist oncology training in 2011 and received his PhD from The University of Sydney in 2015 for research exploring the biology of BRAF-mutant melanoma and biomarkers of response and resistance to targeted therapy. Since 2009 he has been an investigator on over 50 Phase I to III clinical trials of targeted therapies and immunotherapies in melanoma, including the Phase I trials of dabrafenib, combination dabrafenib and trametinib, pembrolizumab and combination ipilimumab and pembrolizumab. He has published several original research and review articles in melanoma, and is a regular invited speaker at national and international meetings. His main research interests are the biology of melanoma and biomarkers of response and resistance to systemic therapy.

Prof  Howard Gurney

Planning Committee – Immuno-Oncology Forum

Biography

Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University. 

Dr Gurney has a firm background in clinical research and has subspecialty interests in uro-genital cancers including prostate, bladder, testis and kidney cancer. 

He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters.  Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area.  He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.

Prof   Michael Millward

Planning Committee – Immuno-Oncology Forum

Biography

Professor Millward is the foundation Chair of Clinical Cancer Research, University of Western Australia and Head of Medical Oncology at Sir Charles Gairdner Hospital, Perth, Australia. He has a strong track record in delivering clinical trial outcomes, particularly with novel therapeutics and phase I/II studies. He is an international expert on thoracic malignancies and melanoma.

Since November 2008 he has been the President of the Australasian Lung Cancer Trials Group. He has published >100 original papers and >200 abstracts at International meetings.

Dr  Matteo Carlino

Planning Committee – Immuno-Oncology Forum

Biography

Matteo Carlino is a Medical Oncologist at Westmead and Blacktown Hospitals. He has recently completed a PhD examining predictors of response and mechanisms of resistance to BRAF and MEK inhibitor treated melanoma.

He continues to be involved in the translational research program based at the Melanoma Institute Australia and the Westmead Institute for Cancer Research. He is an investigator on multiple phase I, II and III clinical trials in melanoma targeted and immunotherapy.

A/Prof  Wendy Cooper

Regional Speaker – Immuno-Oncology Forum

Biography

Wendy Cooper is an anatomical and molecular pathologist who works at Royal Prince Alfred Hospital in Sydney, Australia. She is a Clinical Associate Professor at the University of Sydney and Conjoint Associate Professor at the University of Western Sydney. Wendy is also a Visiting Scientist at the Garvan Institute of Medical Research.

After graduating from Medicine at the University of Sydney with First Class Honours in 1998, she obtained her Fellowship from the Royal Australasian College of Pathologists in 2004. In 2008 she obtained a PhD from the University of Sydney with a thesis titled “Molecular makers of prognosis in early stage non-small cell lung cancer” for which she received the prestigious Peter Bancroft Prize.

Wendy now specialises in pulmonary pathology and has a particular interest in lung cancer and genetic testing of cancers for personalised medicine. She is a member of Multidisciplinary working party revising Clinical Practice Guidelines for the Prevention, Diagnosis and Management of Lung Cancer for Cancer Council Australia. She is also a member of Lung Expert Group for development of Lung Cancer Structured Reporting Protocol for the RCPA and Cancer Institute of NSW. Wendy is Chair of the Lung Club for the Australasian Division of the International Academy of Pathology. She is a member of the Australian Lung cancer Trials Group. Her major research interest is in prognostic and predictive biomarkers in lung cancer.

Prof Eva Segelov

Regional Speaker – Immuno-Oncology Forum

Biography

Professor Eva Segelov MBBS (Hons1) PhD FRACP was appointed as the Professor and Director of Oncology at Monash Health and Monash University in February 2017. She is an Honorary Associate of the NHMRC Clinical Trials Centre, Sydney Medical School and Honorary Professor at Shanghai Jiatong University; previously Associate Professor at the University of New South Wales and Senior Medical Oncologist at St Vincent’s Hospital, Sydney. She is recognised national and international expert in the fields of gastrointestinal cancer, including neuroendocrine tumours, and breast cancer, with a 20 year history of management of patients in a multidisciplinary setting.

Prof Segelov has led multiple national and international oncology clinical trials, including investigator-initiated studies. Her research interests relate to translational studies of targeted therapies in defined subpopulations to increase benefit and reduce toxicity of cancer treatments. She has published over 70 articles, expert reviews and book chapters and is frequent invited speaker at national and international conferences. Professor Segelov has a particular interest in professional development using innovative learning techniques and has developed the Seminal Advances Preceptorship in Cancer courses, now being run through Monash University. She was awarded the UNSW Vice Chancellors award for Teaching Excellence in 2006

Dr. TBA

Regional Speaker – Immuno-Oncology Forum

Biography